Prosecution Insights
Last updated: July 17, 2026
Application No. 18/534,799

UNICOMPARTMENTAL ANKLE PROSTHESIS

Non-Final OA §102§112
Filed
Dec 11, 2023
Priority
Jun 15, 2021 — provisional 63/210,621 +1 more
Examiner
DUKERT, BRIAN AINSLEY
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Wright Medical Technology Inc.
OA Round
1 (Non-Final)
82%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
93%
With Interview

Examiner Intelligence

Grants 82% — above average
82%
Career Allowance Rate
665 granted / 810 resolved
+12.1% vs TC avg
Moderate +11% lift
Without
With
+11.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
17 currently pending
Career history
833
Total Applications
across all art units

Statute-Specific Performance

§101
0.3%
-39.7% vs TC avg
§103
63.6%
+23.6% vs TC avg
§102
25.9%
-14.1% vs TC avg
§112
5.5%
-34.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 810 resolved cases

Office Action

§102 §112
DETAILED ACTION The following is a non-final office action is response to communications received on 12/11/2023. Claims 1-18 are currently pending and addressed below. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Drawings The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, wherein the talar component has a continuous concave curvature (Claims 4, 11 & 14) must be shown or the feature(s) canceled from the claim(s). No new matter should be entered. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 4, 11 & 14-18 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding Claim 4, lines 1-2 state wherein the superior surface of the talar component has a continuous concave curvature. After thoroughly examining the specification and drawings, it is unclear how the superior talar surface can be concave. It would appear, as shown in at least Fig 7, that the superior talar surface is convex. Claims 11 & 14 are similarly indefinite as they are directed to the same issue. For examination purposes, the examiner assumes that concave should read convex. Appropriate correction/clarification is required. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-18 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Leemrijse et al. (US 10,952,865). PNG media_image1.png 399 500 media_image1.png Greyscale Regarding Claim 1, Leemrijse teaches a partial ankle prosthesis (Fig 1) comprising: a tibial component (300) including at least one a peg (314) projecting outwardly from a superior surface and configured to be received in a hole formed in a lower end of a tibia; a poly (Col 6: lines 13-17) component (400) that is fixedly attached to the tibial component (Fig 1) and includes a concave inferior surface (Fig 1) of an anti-friction material (i.e., HDPE as taught in Col 6: lines 13-17); and a talar component (200) including an inferior surface configured to be attached to a patient’s talus and a single convex superior surface (201) configured to mate with the inferior surface of the poly component (Figs 1 & 2); wherein the partial ankle prosthesis is fully capable of being positioned within a unitary compartment of an ankle. Regarding Claim 2, Leemrijse teaches wherein the superior surface of the tibial component includes two adjacent pegs (314A & 314B) configured to be received in corresponding holes formed in the lower tibia. Regarding Claim 3, Leemrijse teaches wherein the inferior surface of the talar component (200) includes at least one peg (216) configured to be received in a corresponding hole formed in a talus bone. Regarding Claim 4, as best understood (see 112 rejection supra), Leemrijse teaches wherein the superior surface of the talar component has a continuous convex curvature (201) between (i) anterior and posterior ends and (ii) medial and lateral sides. Regarding Claim 5, Leemrijse teaches wherein the prosthesis further comprises a bioactive coating (Col 5: lines 9-18) on a surface of at least one of the tibial and the talar components. Regarding Claim 6, Leemrijse teaches wherein an inferior surface of the talar component is curved (at 218 in Figs 7 & 10). Regarding Claim 7, Leemrijse teaches wherein an inferior surface (207) of the talar component is substantially flat (Figs 2 & 3). Regarding Claim 8, Leemrijse teaches wherein the talar component defines a notch (219) in at least one side surface (Fig 1) that is sized and oriented so as to provide a pilot for engagement with a portion of a surgical assembly tool (Col 17: lines 9-20) thereby allowing accurate alignment of the prosthesis by a surgeon. Regarding Claim 9, Leemrijse teaches a partial ankle prosthesis comprising: a tibial component (300) including a superior surface having an outwardly projecting peg (314) configured to be received within a corresponding passageway formed in a portion of a distal tibia; a poly (Col 6: lines 13-17) component (400) that is fixedly attached to the tibial component and includes a concave inferior surface (Fig 1) of an anti-friction material (i.e., HDPE as taught in Col 6: lines 13-17); and a talar component (200) including an inferior surface having an outwardly projecting peg (216) configured to be received within a corresponding passageway formed in a portion of a talus and a single convex superior surface (201) configured to mate with the inferior surface of the poly component (Figs 1 & 2) and further defining a notch (219) in at least one side surface that is sized and oriented so as to provide a pilot for engagement with a portion of a surgical assembly tool (Col 17: lines 9-20) thereby allowing accurate alignment of the prosthesis by a surgeon in a single compartment of a patient’s ankle. Regarding Claim 10, Leemrijse teaches wherein the anterior surface of the talar component (200) defines at least one groove (217 and/or 218) so as to provide additional surface area and thereby increase bone adhesion. Regarding Claim 11, as best understood (see 112 rejection supra), Leemrijse teaches wherein the superior surface of the talar component has only one continuous convex curvature (201) between (i) anterior and posterior ends and (ii) between medial and lateral sides (Figs 1 & 6). Regarding Claim 12, Leemrijse teaches wherein the prosthesis further comprises a bioactive coating (Col 5: lines 9-18) on at least one of a surface of the tibial component and the talar component that interfaces with bone. Regarding Claim 13, Leemrijse teaches wherein an inferior surface of the talar component is complimentarily curved (at peg 216) to attach to a talar dome of the talus. Regarding Claim 14, as best understood (see 112 rejection supra), Leemrijse teaches a partial ankle prosthesis (Fig 1) comprising: a tibial component300) including a superior surface configured to be attached to a lower portion of a tibia; a poly (Col 6: lines 13-17) component (400) that is fixedly attached to the tibial component and includes a concave inferior (Fig 1) surface of an anti-friction material (i.e., HDPE as taught in Col 6: lines 13-17); and a talar component (200) including an inferior surface configured to be attached to a patient’s talus and a single convex superior surface (201) having one continuous concave curvature both longitudinally between anterior and posterior ends and laterally between medial and lateral sides (Figs 1 & 6), and further defining a notch (219) in at least one side surface that is sized and oriented so as to provide a pilot for engagement with a portion of a surgical assembly tool (Col 17: lines 9-20) thereby allowing accurate alignment of the prosthesis by a surgeon in a single compartment of an ankle. Regarding Claim 15, Leemrijse teaches wherein the superior surface of the tibial component (300) includes a peg (314) configured to be received with a hole in the lower tibia. Regarding Claim 16, Leemrijse teaches wherein the anterior surface of the talar component includes a peg (216) configured to be received with a hole in a talus bone. Regarding Claim 17, Leemrijse teaches wherein the prosthesis further comprises a bioactive coating (Col 5: lines 9-18) on a surface of the tibial component and/or the talar component that interfaces with a patient’s bone. Regarding Claim 18, Leemrijse teaches wherein an inferior surface of the talar component is curved (at peg 216) and configured to attach to a talar dome of the talus bone. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN AINSLEY DUKERT whose telephone number is (571)270-3258. The examiner can normally be reached Mon-Fri 6am-4pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melanie Tyson can be reached at (571)272-9062. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN A DUKERT/Primary Examiner, Art Unit 3774
Read full office action

Prosecution Timeline

Dec 11, 2023
Application Filed
Jun 17, 2026
Non-Final Rejection mailed — §102, §112
Jul 07, 2026
Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678286
IMPLANTABLE COMPOSITIONS HAVING FIBERS AND METHODS OF MAKING AND USING THEM
3y 10m to grant Granted Jul 14, 2026
Patent 12672951
ELECTROSPUN PTFE COATED STENT AND METHOD OF USE
4y 8m to grant Granted Jul 07, 2026
Patent 12667373
Safety Hip Femoral Bone Preparation Instruments for the Femur in Minimally Invasive Total Hip Arthroplasty
4y 1m to grant Granted Jun 30, 2026
Patent 12661222
EXPANSION AND LOCKING ASSEMBLIES WITH INTERTWINED WIRES
3y 5m to grant Granted Jun 23, 2026
Patent 12653683
HIP JOINT DEVICE AND METHOD
4y 11m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
82%
Grant Probability
93%
With Interview (+11.2%)
2y 7m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 810 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month